MetaCap

Bioventus (BVS) vs Sight Sciences (SGHT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sight Sciences (SGHT) has outperformed Bioventus (BVS) over the past year, gaining 40.2% versus a gain of 36.5%. Over five years, BVS leads with a -21.0% price change compared with -46.7% for SGHT. Bioventus is the larger company by market cap ($676.5 million vs $565.8 million), about 1.2 times the size.

Bioventus converts more of its revenue into profit, with a net margin of 4.0% versus -49.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BVS+36.46%SGHT+40.22%
+119%+29%-61%
Nov 21, 20251 yearNov 20, 2026
BVS-29.53%SGHT-49.55%
+12%-43%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BVS versus SGHT key metrics
MetricBVSSGHT
Share price$9.88$10.18
Market cap$676.53M$565.79M
1-day change-0.70%-4.14%
YTD return+32.80%+28.37%
1-year return+36.46%+40.22%
5-year return-21.02%-46.67%
P/E ratio (TTM)12.20—
Forward P/E11.13—
EPS (TTM)$0.81$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$568.09M$77.36M
Revenue growth (YoY)-0.91%-3.13%
Net income (latest FY)$22.73M$-38.43M
Gross margin68.33%86.17%
Operating margin9.50%-47.95%
Net margin4.00%-49.67%
52-week high$15.89$11.60
52-week low$7.02$3.38
Distance from 52-week high-37.83%-12.20%
Analyst consensusnonebuy
Avg. price target upside+68.02%+20.33%
Average volume536.81K313.51K
Shares outstanding68.47M55.58M
Employees960186
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Bioventus is more profitable, keeping 4.0 cents of every revenue dollar as net income versus -49.7 cents for Sight Sciences.

About Bioventus

BVS stock →

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.

Health Care · Medical/Dental Instruments · 960 employees

About Sight Sciences

SGHT stock →

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.

Health Care · Medical/Dental Instruments · 186 employees

BVS vs SGHT FAQ

Which is bigger, Bioventus or Sight Sciences?

Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $565.79M for Sight Sciences (SGHT).

Which stock has performed better over the past year, BVS or SGHT?

SGHT returned +40.22% over the past 12 months, compared with +36.46% for BVS (price return, excluding dividends). Past performance does not predict future results.

Are Bioventus and Sight Sciences in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons